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Abstract
Background: Recently, hypothalamus-pituitary-adrenal (HPA) axis function assessed with the combined
dexamethasone (DEX)/corticotropin releasing hormone (CRH) test has been shown to be associated with response
to antidepressant treatment. A polymorphism (rs16944) in the interleukin-1beta (IL-1b) gene has also been reported
to be associated with the medication response in depression. These findings prompted us to examine the possible
association between IL-1b gene polymorphisms and HPA axis function assessed with the DEX/CRH test.
Methods: DEX/CRH test was performed in 179 healthy volunteers (45 males: mean age 40.5 ± 15.8 years; 134
females: mean age 47.1 ± 13.2 years). Five tagging single nucleotide polymorphisms (SNPs) of IL-1b gene
(rs2853550, rs1143634, rs1143633, rs1143630, rs16944) were selected at an r
2 threshold of 0.80 with a minor allele
frequency > 0.1. Genotyping was performed by the TaqMan allelic discrimination assay. A two-way factorial analysis
of variance (ANOVA) was performed with the DEX/CRH test results as the dependent variable and genotype and
gender as independent variables. To account for multiple testing, P values < 0.01 were considered statistically
significant for associations between the genotypes and the cortisol levels.
Results: The cortisol levels after DEX administration (DST-Cortisol) showed significant associations with the
genotypes of rs16944 (P = 0.00049) and rs1143633 (P = 0.0060), with no significant gender effect or genotype ×
gender interaction. On the other hand, cortisol levels after CRH administration (DEX/CRH-Cortisol) were affected by
gender but were not significantly influenced by the genotype of the examined SNPs, with no significant genotype
× gender interaction.
Conclusions: Our results suggest that genetic variations in the IL-1b gene contribute to the HPA axis alteration
assessed by DST-Cortisol in healthy subjects. On the other hand, no significant associations of the IL-1b gene
polymorphisms with the DEX/CRH-Cortisol were observed. Confirmation of our findings in futures studies may add
new insight into the communication between the immune system and the HPA axis.
Background
Recent studies have provided several lines of evidence
implicating the pro-inflammatory cytokine interleukin-
1beta (IL-1b) in the etiology and pathophysiology of
depression. Studies investigating peripheral levels of IL-
1b have reported elevated concentrations of IL-1b in
patients with major depression [1-3] and dysthymia
[4,5]. In experimental animals, exogenous administra-
tions of IL-1b have produced depressive-like symptoms,
which were attenuated by treatment with antidepres-
sants [6,7]. Furthermore, administration of the IL-1
receptor antagonist has ameliorated the stress-like
effects in cellular and behavioral models [8,9], making it
a possible candidate for therapeutic targets.
A few studies have examined genetic polymorphisms
of the IL-1b gene for association with depression.
Although no significant allelic or genotypic differences
have been found between patients with depression and
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shown that the G allele of rs16944 in the IL-1b gene is
associated with poor response to antidepressant
treatment [10,13,14]. This evidence suggests that genetic
regulation of inflammatory processes mediated by IL-1b
is involved in the pathophysiology of depression and
resistance to antidepressant treatment.
Alterations in the hypothalamic-pituitary-adrenal
(HPA) axis have been well-documented in depression
and related psychopathological conditions (reviewed by
[15,16]). We have also reported heightened HPA axis in
major depression and its normalization after treatment
as assessed with the combined dexamethasone (DEX)/
corticotropin releasing hormone (CRH) test [17,18]. The
relationship between alteration of the HPA axis activa-
tion and immune alterations in depression has been
described in several studies [19-21]. The increased
expression of pro-inflammatory cytokines is thought to
lead to the progression of the immune response and
activation of the HPA axis [22-24]. In particular, IL-1b
is considered to play an important role in the HPA axis
alteration. A significant positive correlation between
mitogen-induced IL-1b production and post-DEX corti-
sol values have been reported, suggesting that IL-1b
hypersecretion may contribute to HPA axis hyperactivity
[25]. Animal studies have further demonstrated that the
release of CRH stimulated by IL-1 is involved in the
HPA activation [26-28].
Intriguingly, a number of studies have shown that the
DEX/CRH test may be a predictor for response to
antidepressant treatment. Ising et al [29] found that
higher cortisol level after DEX administration prior to
CRH stimulation was associated with a favorable treat-
ment outcome. Two recent studies showed that
response to antidepressant treatment was more favor-
able in depressive patients whose peak cortisol levels
during the DEX/CRH test were reduced after the initia-
tion of the treatment [30,31]. Further, in the study by
Binder et al [32], antidepressant response was associated
with higher cortisol response to the DEX/CRH test in
male, but not female, patients. It is plausible that the
DEX/CRH test and the antidepressant response are
related, since antidepressants may exert their clinical
effects, at least in part, by reducing the activity of the
H P As y s t e m[ 3 3 , 3 4 ] .T h ef a c tt h a tb o t ht h eH P Aa x i s
activity and the IL-1b gene polymorphism influence the
response to antidepressants further supports the
evidence of reciprocal relationships between the HPA
system and IL-1b.
These previous findings prompted us to examine the
possible association of polymorphisms in the IL-1b and
the HPA function. In the present study, the relationship
between the IL-1b gene polymorphisms and the results
of the DEX/CRH test was examined in healthy subjects.
Because gender effects on measures of HPA axis func-
tion have been previously reported [32,35], a two-way
factorial analysis of variance (ANOVA) was performed
with the DEX/CRH test results as the dependent vari-
able and genotype and gender as independent variables
to determine the possible interaction effects between the
polymorphisms and gender.
Methods
Subjects
Subjects were 179 adult healthy volunteers (45 males:
mean age 40.5 ± 15.8 years, 134 females: mean age 47.1
± 13.2 years) recruited from the community through
advertisements in free local information magazines and
by our website announcement. Most of the subjects
were from our previous sample, in which the relation-
ship between stress, sleep, and HPA function was exam-
ined [36-38]. All subjects were biologically unrelated
Japanese individuals without current or past history of
psychiatric treatment, and were screened with a direct
contact interview by a research psychiatrist using the
Japanese version of the Mini International Neuropsy-
chiatric Interview (M.I.N.I.) [39,40] to rule out any axis
I psychiatric disorders. Participants were excluded if
they had prior medical histories of central nervous
system disease or severe head injury, if they met the cri-
teria for substance abuse or dependence or mental retar-
dation, if they had received glucocorticoid treatment,
psychotropic treatment, antihypertensive medications,
oral contraceptives, or estrogen replacement therapies in
the previous month, or if they suffered from any inflam-
matory, infectious, or systemic immune diseases, based
on self-reports, at the time of assessment. The study
protocol was approved by the ethics committee at the
National Center of Neurology and Psychiatry, Japan.
After description of the study, written informed consent
was obtained from every subject.
Genotyping
Five tagging single nucleotide polymorphisms (SNPs) in
a region 1 kilobase (kb) upstream to 1 kb downstream
of the IL-1b gene (rs2853550, rs1143634, rs1143633,
rs1143630, rs16944) were selected by Haploview 4.2 [41]
using Japanese and Chinese population in the HapMap
SNP set (release 22), at an r
2 t h r e s h o l do f0 . 8 0w i t ha
minor allele frequency greater than 0.1. Genomic
organization and linkage disequilibrium structure of the
IL-1b gene are shown in Figure 1. Genomic DNA was
prepared from the venous blood according to standard
procedures. The SNPs were genotyped using the Taq-
Man 5’-exonuclease allelic discrimination assay. Thermal
cycling conditions for polymerase chain reaction were 1
cycle at 95°C for 10 minutes followed by 50 cycles of
92°C for 15 seconds and 60°C for 1 minute. The
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PRISM 7900 Sequence Detection Systems (Applied Bio-
systems, Foster city, CA, USA). Genotype data were
read blind to the DEX/CRH test results. Ambiguous
genotype data were not included in the analysis.
DEX/CRH test
The DEX/CRH test was administered according to a pro-
tocol proposed in a previous report [18], which was also
employed in our recent report [36]. The subjects were
administered 1.5 mg of DEX (Banyu Pharmaceutical Cor-
poration, Tokyo, Japan) orally at 23.00 h. On the next
day, they attended our laboratory and sat on a comforta-
ble couch in a calm room. A vein was cannulated at
14.30 h to collect blood samples at 15.00 and 16.00 h via
an intravenous catheter. Human CRH (100 μg) (hCRH
‘Mitsubishi’, Mitsubishi Pharma Corporation, Tokyo,
Japan) was administered intravenously at 15.00 h, imme-
diately after the first blood collection. Subjects fasted and
rested semi-supine throughout the testing. Blood samples
were immediately centrifuged and stored at -20°C.
Plasma concentrations of cortisol were measured by
radioimmunoassay at SRL Corporation (Tokyo, Japan).
The detection limit for cortisol was 1.0 μg/dl. Cortisol
values under the detection limit were treated as 0 μg/dl.
The intra-assay coefficients of variation at 2.37 μg/dl,
13.02 μg/dl, and 36.73 μg/dl were 6.90%, 4.94%, and
5.78%, respectively. The inter-assay coefficients of varia-
tion at 2.55 μg/dl, 13.04 μg/dl, and 34.17 μg/dl were
8.91%, 6.03%, and 6.44%, respectively (SRL Corporation,
Tokyo, Japan). Outcome measures of this neuroendo-
crine test were the DST-Cortisol (i.e., the concentration
of cortisol [μg / d l ]a t1 5 . 0 0h )a n dD E X / C R H - C o r t i s o l
(i.e., the concentration of cortisol at 16.00 h).
Statistical analysis
Deviations of genotype distributions from Hardy-Wein-
berg equilibrium (HWE) were assessed using the c
2 test
a. SNPs in the promoter region
b. Intronic SNPs
c. Synonymous SNPs
Figure 1 Genomic organization and LD structure of the IL-1b gene. Genomic organization and linkage disequilibrium (LD) structure of the
IL-1b gene are shown. Exons are shown as boxes. Shades of pink represent extent of LD (red denotes D’ = 1). Numbers in squares give r
2 values
multiplied by 100. The names of the examined SNPs are enclosed in boxes.
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between genotype and gender, two-way factorial analysis
of variance (ANOVA) was performed with the trans-
formed cortisol levels as the dependent variable and
genotype and gender as independent variables. Because
the cortisol levels were not normally distributed, the
aligned rank transformation method was used to trans-
form the data prior to conducting ANOVA [42]. To
correct for the multiple comparisons, statistical signifi-
cance was set at two-tailed P < 0.01 when the analysis
was performed for each of the 5 SNPs. Otherwise, statis-
tical significance was set at two-tailed P < 0.05. Analyses
were performed using the Statistical Package for the
Social Sciences (SPSS) version 11.0 (SPSS Japan, Tokyo).
Results
None of the examined SNPs deviated significantly from
HWE after Bonferroni correction (all P >0 . 0 1 ) ,
although rs1143633 showed a trend towards excess of
heterozygotes over Hardy-Weinberg expectations (c
2 =
6.48, P < 0.05). Age showed no significant correlation
with DST-Cortisol or DEX/CRH-Cortisol in either
gender (all P > 0.05).
Additional file 1 (Table S1) presents the results of the
two-way ANOVA performed with the transformed
plasma cortisol levels as the dependent variable and gen-
otype and gender as independent variables. Significant
effects of genotype on DST-Cortisol were observed for
rs1143633 and rs16944, with no significant gender effect
or genotype × gender interaction. The means of the
DST-Cortisol in each genotype of rs1143633 and
rs16944 and the significance levels of Tukey’s post hoc
tests are shown in Figure 2. Regarding DEX/CRH-Corti-
sol, significant gender effects were demonstrated in
three of the two-way ANOVA results. No significant
genotype effect or genotype × gender interaction was
observed for DEX/CRH-Cortisol.
Discussion
To our knowledge, this is the first study that revealed
t h ep o s s i b l er o l eo fIL-1b polymorphisms on HPA axis
function. Two studies have reported the influence of
Figure 2 Mean DST-Cortisol levels. The means of the DST-Cortisol levels in each genotype of rs1143633 (Figure 2a) and rs16944 (Figure 2b)
are shown. Error bars indicate the standard errors of the means. Asterisks in the graph indicate significance levels of the Tukey’s post hoc test. *
P < 0.01, ** P < 0.001, *** P < 0.0001.
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[43,44], one of which has shown that an allele in a poly-
morphism within the CRHBP gene, which regulates the
CRH system, was associated with pronounced DEX sup-
pression of corticotropin and with nonresponse to cita-
lopram treatment in depressed subjects [43]. Some
studies have also reported the influence of genetic poly-
morphisms on DEX/CRH-Cortisol. Schule et al [45]
reported that brain-derived neurotrophic factor Val66-
Met polymorphism is associated with HPA axis activity
during the DEX/CRH test in depressed patients. There
is also a study reporting an association of a polymorph-
ism of the preprogalanin gene with DEX/CRH test
results and antidepressant treatment response [46]. Our
study adds to accumulating evidence that genetic factors
could influence the activity of the HPA axis.
Previous studies have shown associations of HPA
axis activity assessed by the DEX/CRH test with anti-
depressant treatment [30-32].F u r t h e r m o r e ,h i g h e rc o r -
tisol level after DEX administration prior to CRH
stimulation was also associated with a favorable treat-
ment outcome [29]. Since the IL-1b gene polymorph-
ism is also known to influence the response to
antidepressants, we expected that association between
IL-1b gene and HPA activity assessed by the DEX/
CRH test would be found. However, our results
showed that only DST-Cortisol, but not DEX/CRH-
Cortisol, was significantly associated with the IL-1b
gene polymorphisms. Thus, the relationship of the
HPA activity and the IL-1b gene polymorphism with
the antidepressant response could not be fully
explained from our findings. Although the present
study was performed in healthy subjects, it is possible
that a different regulatory mechanism of HPA axis
which overweighs the effect of the polymorphisms
examined in the present study may exist in depressive
patients. Further studies must be carried out to deter-
mine HPA axis regulation in patients with depression.
Significant gender effects were observed for DEX/
CRH-Cortisol, consistent with previous studies [18,47].
However, as mentioned above, the DEX/CRH-Cortisol
did not show significant associations with any of the
SNPs examined. This may partly be explained by the
putative action of IL-1b on hypothalamus. Animal stu-
dies have shown that IL-1b is involved in the noradrena-
line-induced release of CRH from the hypothalamus
[28,48]. Therefore, higher IL-1b expression in the brain
may facilitate the release of CRH even when the sup-
pressive effect of DEX is exerted, resulting in higher
DST-Cortisol. On the other hand, the effect of IL-1b on
the DEX/CRH-Cortisol could be small if the administra-
tion of CRH overweighs the effect of IL-1b expression
level. Because rs1143634 and rs1143633 showed a trend
towards association with DEX/CRH-Cortisol (P <0 . 1 ) ,a
f u r t h e rs t u d yw i t hal a r g e rs a m p l es i z em a yb e
warranted.
The findings on biological roles of rs16944 poly-
morphism have not been consistent across studies. A/A
genotype has been associated with higher gastric mucosa
IL-1b levels in H. pylori positive population [49]. On the
other hand, mononuclear cells from subjects with G/G
genotype showed an increased release of IL-1b after sti-
mulation with lipopolysaccharide [50]. Recent studies
suggest that the functional role of rs16944 may depend
on the IL-1b promoter region haplotypes including
rs16944 and rs1143627 [51-54]. Although the findings
are inconsistent, these previous studies suggest that
rs16944 could affect the expression levels of IL-1b.T h e
biological role of rs1143633, on the other hand, has not
been previously reported.
Previous studies showed that administration of DEX
inhibited lipopolysaccharide (LPS)-stiumulated produc-
tion of IL-1b [55,56], suggesting that DEX may affect
the function of IL-1b g e n e .T h e r e f o r e ,f u t u r es t u d i e s
should examine the influence of IL-1b gene polymorph-
isms on not only basal IL-1b levels but also DEX-
induced IL-1b levels. The decrease of the LPS-induced
IL-1b gene expression by DEX may be caused by the
inhibition of nuclear factor binding to the IL-1b gene
promoter [56]. It is noteworthy that, in the present
study, the HPA response to DEX was affected by
rs16944, which is located in the promoter region of the
IL-1b gene.
The following limitations must be considered when
interpreting the results. First, since the DEX/CRH test
used here was based on a simple test protocol, we could
n o tc a l c u l a t et h ec o r t i s o la r e au n d e rt h ec u r v e[ 5 7 , 5 8 ] .
We also did not measure the adrenocorticotropic hor-
mone levels, which was measured in previous studies to
determine the pituitary glucocorticoid negative feedback
[30,45,57-59]. Moreover, we did not measure the base-
line levels of cortisol. The extent to which the cortisol
was suppressed in response to DEX administration
could not be determined from our data. There may have
been a genotype dependent alteration of the baseline
cortisol levels, which appeared in the present study as a
genotype effect on DST-Cortisol. This will need further
investigation. We also did not perform physical exami-
nation to rule out physical disorders. As the presence or
absence of inflammatory and immune diseases were
b a s e do n l yo ns e l f - r e p o r t s ,t h er e s u l t sm a yh a v eb e e n
affected by unrecognized inflammatory processes in
some participants. Furthermore, the lack of data on
menstrual cycle or menopausal status in the female par-
ticipants may have also influenced the results. Another
limitation of the study is that we did not assess the bio-
logical role of IL-1b polymorphisms. The association of
IL-1b expression level with the IL-1b polymorphisms
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sent study included only healthy subjects. Whether the
relationship between IL-1b gene polymorphisms and the
HPA function is altered in depressed patients remain to
be elucidated.
Conclusions
The present study revealed that the cortisol response to
administration of DEX is influenced by the IL-1b gene
polymorphisms. The G allele of rs16944 and the T allele
of rs1143633 were significantly associated with higher
DST-Cortisol. On the other hand, no significant associa-
tions of the IL-1b gene polymorphisms with the DEX/
CRH-Cortisol were observed. Our study adds to accu-
mulating evidence that IL-1b is involved in the regula-
tion of the HPA axis. Confirmation of our findings in
futures studies may add new insight into the communi-
cation between the immune system and the HPA axis.
Additional material
Additional file 1: Table S1. The results of the two-way ANOVA.
ANOVA was performed with the transformed cortisol levels as the
dependent variable and genotype and gender as independent variables.
P values < 0.01 are shown in bold.
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